Pharmacologic disruption of Polycomb Repressive Complex 2 inhibits tumorigenicity and tumor progression in prostate cancer

Molecular Cancer

Volumn 10, Issue , 2011, Pages

  Crea, Francesco ^a   Hurt, Elaine M ^b   Mathews, Lesley A ^a   Cabarcas, Stephanie M ^a   Sun, Lei ^a   Marquez, Victor E ^a   Danesi, Romano ^c   Farrar, William L ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b MEDIMMUNE   (United States)

^c Pisa Medical School   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

3 DEZANEPLANOCIN A; ANTINEOPLASTIC AGENT; HYDROLASE INHIBITOR; POLYCOMB GROUP PROTEIN; PROTEIN POLYCOMB REPRESSIVE COMPLEX 2; UNCLASSIFIED DRUG; HISTONE; MESSENGER RNA; REPRESSOR PROTEIN;

ARTICLE; CANCER CELL CULTURE; CANCER STEM CELL; CARCINOGENICITY; CELL INVASION; CELL PROLIFERATION; GENE OVEREXPRESSION; GENE SILENCING; HISTONE METHYLATION; HUMAN; NONHUMAN; PROGNOSIS; PROSTATE CANCER; TUMOR GROWTH; ANIMAL; CELL MOTION; CELL SURVIVAL; CELL TRANSFORMATION; DISEASE COURSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; MALE; METABOLISM; METHYLATION; MOUSE; MOUSE MUTANT; MULTICELLULAR SPHEROID; PROSTATE TUMOR; TUMOR CELL CULTURE; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONES; HUMANS; MALE; METHYLATION; MICE; MICE, SCID; NEOPLASTIC STEM CELLS; PROSTATIC NEOPLASMS; REPRESSOR PROTEINS; RNA, MESSENGER; SPHEROIDS, CELLULAR; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79955119487     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-10-40     Document Type: Article

References (40)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin 2008, 58:71-96. 10.3322/CA.2007.0010, 18287387.
2. Bracarda S, de Cobelli O, Greco C, Prayer-Galetti T, Valdagni R, Gatta G, de Braud F, Bartsch G. Cancer of the prostate. Crit Rev Oncol Hematol 2005, 56:379-396. 10.1016/j.critrevonc.2005.03.010, 16310371.
3. Lang SH, Frame FM, Collins AT. Prostate cancer stem cells. J Pathol 2009, 217:299-306. 10.1002/path.2478, 2673349, 19040209.
4. Hurt EM, Kawasaki BT, Klarmann GJ, Thomas SB, Farrar WL. CD44+ CD24(-) prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis. Br J Cancer 2008, 98:756-765. 10.1038/sj.bjc.6604242, 2259168, 18268494.
5. Hurt EM, Farrar WL. Cancer stem cells: the seeds of metastasis?. Mol Interv 2008, 8:140-142. 10.1124/mi.8.3.7, 18693193.
6. Crea F, Mathews LA, Farrar WL, Hurt EM. Targeting prostate cancer stem cells. Anticancer Agents Med Chem 2009, 9:1105-1113.
7. Dubrovska A, Kim S, Salamone RJ, Walker JR, Maira SM, Garcia-Echeverria C, Schultz PG, Reddy VA. The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations. Proc Natl Acad Sci USA 2009, 106:268-273. 10.1073/pnas.0810956106, 2629188, 19116269.
8. Duhagon MA, Hurte EM, Sotelo-Silveira JR, Zhang X, Farrar WL. Genomic profiling of tumor initiating prostatospheres. BMC Genomics 11:324. 10.1186/1471-2164-11-324, 2900264, 20500816.
9. Radisky DC, LaBarge MA. Epithelial-mesenchymal transition and the stem cell phenotype. Cell Stem Cell 2008, 2:511-512. 10.1016/j.stem.2008.05.007, 18522839.
10. Wu Y, Zhou BP. New insights of epithelial-mesenchymal transition in cancer metastasis. Acta Biochim Biophys Sin (Shanghai) 2008, 40:643-650. 10.1111/j.1745-7270.2008.00443.x, 2740620, 18604456.
11. Klarmann GJ, Hurt EM, Mathews LA, Zhang X, Duhagon MA, Mistree T, Thomas SB, Farrar WL. Invasive prostate cancer cells are tumor initiating cells that have a stem cell-like genomic signature. Clin Exp Metastasis 2009, 26:433-446. 10.1007/s10585-009-9242-2, 2782741, 19221883.
12. Mathews LA, Crea F, Farrar WL. Epigenetic gene regulation in stem cells and correlation to cancer. Differentiation 2009, 78:1-17. 10.1016/j.diff.2009.04.002, 2706282, 19443100.
13. Berezovska OP, Glinskii AB, Yang Z, Li XM, Hoffman RM, Glinsky GV. Essential role for activation of the Polycomb group (PcG) protein chromatin silencing pathway in metastatic prostate cancer. Cell Cycle 2006, 5:1886-1901. 10.4161/cc.5.16.3222, 16963837.
14. Blumenberg M, Gao S, Dickman K, Grollman AP, Bottinger EP, Zavadil J. Chromatin structure regulation in transforming growth factor-beta-directed epithelial-mesenchymal transition. Cells Tissues Organs 2007, 185:162-174. 10.1159/000101317, 17587822.
15. Cao Q, Yu J, Dhanasekaran SM, Kim JH, Mani RS, Tomlins SA, Mehra R, Laxman B, Cao X, Yu J, et al. Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene 2008, 27:7274-7284. 10.1038/onc.2008.333, 2690514, 18806826.
16. Crea F, Duhagon Serrat MA, Hurt EM, Thomas SB, Danesi R, Farrar WL. BMI1 silencing enhances docetaxel activity and impairs antioxidant response in prostate cancer. Int J Cancer 128:1946-1954. 10.1002/ijc.25522, 20568112.
17. van Leenders GJ, Dukers D, Hessels D, van den Kieboom SW, Hulsbergen CA, Witjes JA, Otte AP, Meijer CJ, Raaphorst FM. Polycomb-group oncogenes EZH2, BMI1, and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features. Eur Urol 2007, 52:455-463. 10.1016/j.eururo.2006.11.020, 17134822.
18. Bray M, Driscoll J, Huggins JW. Treatment of lethal Ebola virus infection in mice with a single dose of an S-adenosyl-L-homocysteine hydrolase inhibitor. Antiviral Res 2000, 45:135-147. 10.1016/S0166-3542(00)00066-8, 10809022.
19. Tan J, Yang X, Zhuang L, Jiang X, Chen W, Lee PL, Karuturi RK, Tan PB, Liu ET, Yu Q. Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev 2007, 21:1050-1063. 10.1101/gad.1524107, 1855231, 17437993.
20. Suva ML, Riggi N, Janiszewska M, Radovanovic I, Provero P, Stehle JC, Baumer K, Le Bitoux MA, Marino D, Cironi L, et al. EZH2 is essential for glioblastoma cancer stem cell maintenance. Cancer Res 2009, 69:9211-9218. 10.1158/0008-5472.CAN-09-1622, 19934320.
21. Volate SR, Kawasaki BT, Hurt EM, Milner JA, Kim YS, White J, Farrar WL. Gossypol induces apoptosis by activating p53 in prostate cancer cells and prostate tumor-initiating cells. Mol Cancer Ther 9:461-470. 10.1158/1535-7163.MCT-09-0507, 2820604, 20124455.
22. Kim MS, Blake M, Baek JH, Kohlhagen G, Pommier Y, Carrier F. Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res 2003, 63:7291-7300.
23. Bender CM, Pao MM, Jones PA. Inhibition of DNA methylation by 5-aza-2'-deoxycytidine suppresses the growth of human tumor cell lines. Cancer Res 1998, 58:95-101.
24. Mathews LA, Hurt EM, Zhang X, Farrar WL. Epigenetic regulation of CpG promoter methylation in invasive prostate cancer cells. Mol Cancer 9:267. 10.1186/1476-4598-9-267, 2958982, 20929579.
25. Carlsson G, Gullberg B, Hafstrom L. Estimation of liver tumor volume using different formulas - an experimental study in rats. J Cancer Res Clin Oncol 1983, 105:20-23. 10.1007/BF00391826, 6833336.
26. Varambally S, Yu J, Laxman B, Rhodes DR, Mehra R, Tomlins SA, Shah RB, Chandran U, Monzon FA, Becich MJ, et al. Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 2005, 8:393-406. 10.1016/j.ccr.2005.10.001, 16286247.
27. Lee TI, Jenner RG, Boyer LA, Guenther MG, Levine SS, Kumar RM, Chevalier B, Johnstone SE, Cole MF, Isono K, et al. Control of developmental regulators by Polycomb in human embryonic stem cells. Cell 2006, 125:301-313. 10.1016/j.cell.2006.02.043, 16630818.
28. Upadhyay AK, Cheng X. Dynamics of histone lysine methylation: structures of methyl writers and erasers. Prog Drug Res 67:107-124. 3048032, 21141727.
29. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt RG, Otte AP, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002, 419:624-629. 10.1038/nature01075, 12374981.
30. Puppe J, Drost R, Liu X, Joosse SA, Evers B, Cornelissen-Steijger P, Nederlof P, Yu Q, Jonkers J, van Lohuizen M, Pietersen AM. BRCA1-deficient mammary tumor cells are dependent on EZH2 expression and sensitive to Polycomb Repressive Complex 2-inhibitor 3-deazaneplanocin A. Breast Cancer Res 2009, 11:R63. 10.1186/bcr2354, 2750125, 19709408.
31. Jung JW, Lee S, Seo MS, Park SB, Kurtz A, Kang SK, Kang KS. Histone deacetylase controls adult stem cell aging by balancing the expression of polycomb genes and jumonji domain containing 3. Cell Mol Life Sci 67:1165-1176. 10.1007/s00018-009-0242-9, 2835723, 20049504.
32. Hagemann S, Heil O, Lyko F, Brueckner B. Azacytidine and decitabine induce gene-specific and non-random DNA demethylation in human cancer cell lines. PLoS One 6:e17388. 10.1371/journal.pone.0017388, 3049766, 21408221.
33. Han B, Xie H, Chen Q, Zhang JT. Sensitizing hormone-refractory prostate cancer cells to drug treatment by targeting 14-3-3sigma. Mol Cancer Ther 2006, 5:903-912. 10.1158/1535-7163.MCT-05-0393, 16648560.
34. Baritaki S, Chapman A, Yeung K, Spandidos DA, Palladino M, Bonavida B. Inhibition of epithelial to mesenchymal transition in metastatic prostate cancer cells by the novel proteasome inhibitor, NPI-0052: pivotal roles of Snail repression and RKIP induction. Oncogene 2009, 28:3573-3585. 10.1038/onc.2009.214, 19633685.
35. Lenferink AE, Cantin C, Nantel A, Wang E, Durocher Y, Banville M, Paul-Roc B, Marcil A, Wilson MR, O'Connor-McCourt MD. Transcriptome profiling of a TGF-beta-induced epithelial-to-mesenchymal transition reveals extracellular clusterin as a target for therapeutic antibodies. Oncogene 29:831-844. 10.1038/onc.2009.399, 19935703.
36. Chunthapong J, Seftor EA, Khalkhali-Ellis Z, Seftor RE, Amir S, Lubaroff DM, Heidger PM, Hendrix MJ. Dual roles of E-cadherin in prostate cancer invasion. J Cell Biochem 2004, 91:649-661. 10.1002/jcb.20032, 14991757.
37. Herranz N, Pasini D, Diaz VM, Franci C, Gutierrez A, Dave N, Escriva M, Hernandez-Munoz I, Di Croce L, Helin K, et al. Polycomb complex 2 is required for E-cadherin repression by the Snail1 transcription factor. Mol Cell Biol 2008, 28:4772-4781. 10.1128/MCB.00323-08, 2493371, 18519590.
38. Keller ET, Dai J, Escara-Wilke J, Hall CL, Ignatoski K, Taichman RS, Keller J. New trends in the treatment of bone metastasis. J Cell Biochem 2007, 102:1095-1102. 10.1002/jcb.21540, 17955492.
39. Coulombe RA, Sharma RP, Huggins JW. Pharmacokinetics of the antiviral agent 3-deazaneplanocin A. Eur J Drug Metab Pharmacokinet 1995, 20:197-202. 10.1007/BF03189670, 8751041.
40. Beier D, Rohrl S, Pillai DR, Schwarz S, Kunz-Schughart LA, Leukel P, Proescholdt M, Brawanski A, Bogdahn U, Trampe-Kieslich A, et al. Temozolomide preferentially depletes cancer stem cells in glioblastoma. Cancer Res 2008, 68:5706-5715. 10.1158/0008-5472.CAN-07-6878, 18632623.